Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02544906

Acronym

Agitation

Enrollment

120

Registered

2015-09-09

Start date

2015-09-30

Completion date

2016-10-31

Last updated

2015-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation

Keywords

recipients

Brief summary

The use of propofol or dexmedetomedine for prevention of sevofurane emergence agitation in LDLT recipients

Interventions

DRUGPropofol

Infusion of propofol to prevent emergence agitation in liver transplanta recipients

DRUGdexmedetomedine

Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

30 Years to 60 Years

Healthy volunteers

Inclusion criteria

* All recipients of living donor liver transplantation

Exclusion criteria

* patient refusal Allergy to either propofol or dexmedetomediene CNS disease

Design outcomes

Primary

Measure	Time frame
incidence of emergence agitation in liver trasnplant recipients	24 hours

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026